• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Exelixis

Exelixis

  1. All
  2. Morningstar Articles
  3. Investing
  1. Is This the Year Exelixis Excels?

    The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.

  2. Beware 5-Star Stocks Bearing No Moats

    Lack of competitive advantages may mean these companies aren't the bargains they seem to be.

  3. Don't Bail on Biotech

    We see opportunity as fleeing investors trigger an irrational sell-off.

  4. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

  5. Biotech ETFs: Which One Is Best Now?

    The five biotech ETFs have very different portfolios with markedly different performance.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.